Conferences

PREclinical Disease Modeling for Clinical Translation, PREDICT

Through novel technology adoption (from computation programs, to animal models, to better imaging modalities) our community discover the different approaches they can take to arm their translational decisions, enabling them to have a better understanding of candidate and the confidence to enter clinical trials knowing it is safe and effective.

HW210406-PREDiCT-Innovation-genOway-logo-2048x277.png

The core questions to be answered at every PREDiCT meeting supported by genOway:

  • What new model and additive technology initiatives are helping biopharma leaders drive translational and early-stage decision making?
  • How do biopharma leaders balance advances in model complexity and relevance with the cost-per-data-point?
  • What are the key criteria the leading biotech and pharma use to assess, select and characterise the array of tumor mouse models and tumor rat models?

Agenda for CET (Central Europe Time)

2:00 pm Login & Join Our Coffee Chat Room

2:30 pm Chair’s Opening Remarks

Niina Veitonmaki
Head of Biology, Aelin Therapeutics

Kader Thiam SVP
Discovery, Preclinical Models & Services, genOway

Revolutionizing PK/PD & Efficacy Studies in Humanized Models

2:40 pm Human-Specific Immunotherapeutics Evaluation in VISTA & GITR Humanized Mouse Model

Ludovic Bourre
Senior Director, Scientific Engagement, Crown Bioscience Inc.

Synopsis

  • Efficacy evaluation of anti-hGITR and anti-hVISTA as single agent or in combination with anti-mPD1 on MC38 tumor model 
  • Immunoprofiling: dissecting the mechanism of action (MOA)

3:00 pm Pept-insTM, First-in-Class Technology Targeting Broad Disease Areas & High-Value Undruggable Targets

Niina Veitonmaki
Head of Biology, Aelin Therapeutics

Synopsis

  • Assessing the mode of action of novel Pept-insTM utilizing the aggregation prone sequences 
  • In vivo proof-of concept using Vascin Pep-inTM targeting VEGFR2 
  • Pept-insTM as opportunities against high-value undruggable targets 

3:20 pm Physiologically Relevant Mouse Models to Investigate PK & Efficacy of HSA-Based Drugs

Ken Howard
Associate Professor, Head of Bioengineered Drug Delivery Designs Laboratory iNANO, Aarhus University

Synopsis

  • FcRn-driven cellular recycling facilitates the prolonged circulation of HSA 
  • Models that maintain autologous HSA and human FcRn receptor (hFcRn) engagement are required to avoid competition from endogenous mouse albumin 
  • Double transgenic HSA, hFcRn mice provides a physiological relevant environment and appropriate endogenous HSA competition to investigate recombinant HSA-drugs or conventional drugs whose PK is influenced by association with HSA 

3:40 pm Spotlight Talk from genOway

4:00 pm Engraftment of AML-PDX: Selection of Strains of Immunocompromised Mice & Induction of Human Cytokine Release Syndrome in Humanized BRGSF Mice

Annie An
Associate Director, Crown Bioscience, Inc.

Dean Campbell
Director, Scientific Engagement, Crown Bioscience, Inc.

Assessment of the Human Immune Response to Immunomodulators in Next Generation HIS Mice

4:20 pm Pharmacodynamic Assessment of Bispecific IgM Antibody Using BRGSF-HIS Mice

Poonam Yakundi
Scientist II, IGM Biosciences

Synopsis

  • Introduction: Generation of BRGSF-HIS mice 
  • Introduction: IgM antibody 
  • Data slides: PD assessment data

4:40 pm Humanized Mouse Models in the Development of PD-1 Agonists

Kevin OtipobyVice President of Research, Immunology, Pandion Therapeutics, Inc., a wholly-owned subsidiary of. Merck & Co., Inc.
Lindsay EdwardsPrincipal Scientist, Pandion Therapeutics, Inc., a wholly-owned subsidiary of. Merck & Co., Inc.

Synopsis

Our talk will explore the development of PD-1 agonists in:

  • Xenogeneic graft versus host disease
  • Genetically engineered models
  • Human hematopoietic stem cell engrafted models

5:00 pm BRGSF-HIS Mice: A New Model to Assess the Human Immune Response to Immunomodulators

Kader Thiam SVP
Discovery, Preclinical Models & Services, genOway

Synopsis

  • Features of the human lymphoid and myeloid immune cells developed in the BRGSF-HIS mice after reconstitution with hCD34+ cells 
  • Human immune response in a context of tumor growth & anti-tumor treatment  

5:20 pm Panel Discussion: What Does the Next Gen Humanized Models Need to Look Like?

Kader Thiam
Discovery, Preclinical Models & Services, genOway

Niina Veitonmaki
Head of Biology, Aelin Therapeutics

Kevin Otipoby
Vice President of Research, Immunology, Pandion Therapeutics, Inc., a wholly-owned subsidiary of. Merck & Co., Inc.

Lindsay Edwards
Principal Scientist, Pandion Therapeutics, Inc., a wholly-owned subsidiary of. Merck & Co., Inc.

Poonam Yakundi
Scientist II, IGM Biosciences

Synopsis

In this interactive panel discussions, we will feature IO experts across pharma, biotech and CRO to discuss common challenges and solutions, including:

  • How to design and validate a complex genetically engineered mouse model?
  • Costs and reproducibility of humanized models 
  • Quality control and how to minimize variability? 
  • Flexibility – off the shelf vs customized models? 

6:00 pm Chair’s Closing Remarks & End of Meeting

Niina Veitonmaki
Head of Biology, Aelin Therapeutics

Kader Thiam SVP
Discovery, Preclinical Models & Services, genOway